Breaking barriers: Upfront expense payments to ease the economic burden for clinical trial patients.

C Chiara Martinelli (Roche Pharma Research and Early Development (pRED), Welwyn Garden City, United Kingdom) L Lyra del Rosario (Drug Development Unit (The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research), London, United Kingdom) J Jennifer Ball (Roche Products Limited, Welwyn Garden City, United Kingdom) R Ruth Davies (Roche Products Limited, Welwyn Garden City, United Kingdom) A Angelina McLeod (Roche Products Limited, Welwyn Garden City, United Kingdom) J Jose Manuel Ordonez (Roche FARMA SA, Madrid, Spain) C Cristina Ramon (Roche FARMA SA, Madrid, Spain) J Johann S. de Bono M Markella Boudioni (The Royal Marsden NHS Foundation Trust, London, United Kingdom) J Jennifer Lauman (Drug Development Unit (The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research), London, United Kingdom) A Adam Sharp M Mary Van Zyl (The Royal Marsden NHS Foundation Trust, London, United Kingdom) A Ana Matres Rojo (Vall Hebron Institut d'Oncologia (VHIO), Barcelona, Spain) C Cristina Perez (VHIO Vall d'Hebron Instituto de Oncología, Barcelona, Spain) L Laura Arribillaga (Clinica Universidad de Navarra, Pamplona, Spain) G Gabriel Canel (Clinica Universidad de Navarra, Pamplona, Spain) M Maria Luisa Bezares (Clinica Universidad de Navarra, Pamplona, Spain) M Maria Lapuente (Centre for Experimental Cancer Medicine (St Bartholomew’s Hospital), London, United Kingdom) E Eric Mackelprang (Greenphire, King of Prussia, PA) B Bindumalini Rao Baikady (The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom)

Abstract

e23160 Background: Participation in clinical trials (CT) often imposes significant challenges on patients, beyond emotional and time commitments. The economic burden associated with being out-of-pocket (OOP) is a major barrier, particularly for individuals from lower socio-economic backgrounds, limiting their participation and retention in CT. Currently, Patients are required to cover their expenses upfront themselves, retain receipts, and submit claims for reimbursement. This process can take weeks, causing financial strain on patients, making CT less accessible to certain patient groups. To address this issue, we have developed an efficient and streamlined upfront payment management process to minimise the economic and administrative burden for both patients and CT sites. Methods: A collaboration between the Drug Development Unit at the Royal Marsden (RM) and the Institute of Cancer Research, Public and Patient Group at the RM, Barts NHS Trust, Vall d' Hebron Institute of Oncology, Clinica Universidad de Navarra, Roche/Genentech and third-party vendor, Greenphire, tackled key challenges such as Logistics of payment processes, Tax implications, Fiscal impact on trial sponsor, Country specific aspects and Regulatory and Ethics approval for the process, piloting in one of the Roche/Genentech sponsored trial AND finding solutions for these challenges. Results: A comprehensive upfront payment process (Table 1) was designed to support patients from pre-consent through to trial completion. Key features are: Tax-exempt paymentsReasonable OOP expenses are exempt from Tax implications. Individualized expense assessmentPayments are calculated per CT visit based on national guidelines and documented for audits. Seamless patient paymentsA portal within Greenphire facilitated real time direct payments via debit card or bank transfer where allowable. Regulatory integrationUK regulatory approval was secured. Approval in Spain is on-going. Conclusions: The upfront payment process effectively minimizes OOP expenses, reduces site burden, and improves the patient experience. Addressing other barriers, eg childcare, carer and pet-care, will further enhance CT accessibility, ultimately fostering a more equitable environment. Expanding this process across more CT will improve inclusivity and diversity and will provide measurable outcomes. · Pre-consent Patients OOP expenses are assessed prior to consent visit. · Informed Consent Patient’s consent is obtained before sharing personal details with Greenphire · Payment Set-up Greenphire is informed of patient’s details · First Visit On first consent visit, patients receive OOP expense covering two visits, one for the current visit and one for the next visit, via the Greenphire portal.· Subsequent visits From the second visit onwards, patients received a sum covering their next visit in advance, ensuring patients are never out-of-pocket.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (20)

C

Chiara Martinelli

Roche Pharma Research and Early Development (pRED), Welwyn Garden City, United Kingdom

L

Lyra del Rosario

Drug Development Unit (The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research), London, United Kingdom

J

Jennifer Ball

Roche Products Limited, Welwyn Garden City, United Kingdom

R

Ruth Davies

Roche Products Limited, Welwyn Garden City, United Kingdom

A

Angelina McLeod

Roche Products Limited, Welwyn Garden City, United Kingdom

J

Jose Manuel Ordonez

Roche FARMA SA, Madrid, Spain

C

Cristina Ramon

Roche FARMA SA, Madrid, Spain

J

Johann S. de Bono

M

Markella Boudioni

The Royal Marsden NHS Foundation Trust, London, United Kingdom

J

Jennifer Lauman

Drug Development Unit (The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research), London, United Kingdom

A

Adam Sharp

M

Mary Van Zyl

The Royal Marsden NHS Foundation Trust, London, United Kingdom

A

Ana Matres Rojo

Vall Hebron Institut d'Oncologia (VHIO), Barcelona, Spain

C

Cristina Perez

VHIO Vall d'Hebron Instituto de Oncología, Barcelona, Spain

L

Laura Arribillaga

Clinica Universidad de Navarra, Pamplona, Spain

G

Gabriel Canel

Clinica Universidad de Navarra, Pamplona, Spain

M

Maria Luisa Bezares

Clinica Universidad de Navarra, Pamplona, Spain

M

Maria Lapuente

Centre for Experimental Cancer Medicine (St Bartholomew’s Hospital), London, United Kingdom

E

Eric Mackelprang

Greenphire, King of Prussia, PA

B

Bindumalini Rao Baikady

The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom